Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.

Latest option deal with Swiss major solidifies BeiGene’s front-runner position in PD-1 combination therapy with novel antibodies.

Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.

November negotiations in China over the prices of 67 new drugs have resulted in record price cuts, averaging around 62% overall and 65% for anti-tumor products. But the sting is alleviated by the prospect of substantial volume increases.